GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OTCPK:OASMY) » Definitions » Notes Receivable

OASMY (Vivesto AB) Notes Receivable : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Vivesto AB Notes Receivable?

Vivesto AB's Notes Receivable for the quarter that ended in Mar. 2025 was $0.00 Mil.


Vivesto AB Notes Receivable Historical Data

The historical data trend for Vivesto AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivesto AB Notes Receivable Chart

Vivesto AB Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vivesto AB Quarterly Data
Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Vivesto AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Vivesto AB Notes Receivable Related Terms

Thank you for viewing the detailed overview of Vivesto AB's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivesto AB Business Description

Traded in Other Exchanges
Address
Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.

Vivesto AB Headlines

From GuruFocus

Oasmia Pharmaceutical AB (publ) - Special Call Transcript

By GuruFocus Research 03-06-2024

Q2 2021 Oasmia Pharmaceutical AB Earnings Call Transcript

By GuruFocus Research 03-06-2024

Q2 2022 Vivesto AB Earnings Call Transcript

By GuruFocus Research 03-06-2024